T he heart is the first organ to develop during embryogenesis. In the developing mouse heart, between embryonic day (E) 11.5 and E14.5, cardiac cells undergo differentiation, migration, and proliferation driving cardiac tissue morphogenic events including chamber septation, heart valve formation, myocardial compaction, and coronary vessel formation, all essential for proper heart development. [1] [2] [3] [4] These processes are directed by cardiac transcriptional programs and endocardial-myocardial molecular signalings. [5] [6] [7] [8] Both genetic and epigenetic mechanisms have been shown to control the expression of cardiac genes in a spatiotemporal manner during heart development. [9] [10] [11] [12] [13] Epigenetic modifications, including DNA methylation and histone modification, regulate gene expression by changing the local chromatin structure, thus altering the interaction of chromatin and DNA-binding proteins, such as the binding of transcription activators and repressors to gene promoters and enhancers. [14] [15] [16] Different from genetic variation, epigenetic modifications regulate gene expression without altering the nucleotide sequence. In the case of DNA methylation, a methyl group is added to the carbon 5 of cytosine located at a CpG dinucleotide. It has been shown that DNA methylation is essential for gene regulation during development, especially that of tissue-specific genes, and help to maintain cell and tissue identity. [17] [18] [19] Notably, with the exception of imprinted genes, the mammalian genome is stripped of its epigenetic modifications in early embryogenesis and the epigenome is then re-established throughout embryonic development. [20] [21] [22] Globally, the patterns of DNA methylation acquired during embryogenesis remain stable throughout development and adulthood. 19 However, changes in DNA methylation at individual loci do occur and can alter expression of genes with important biological functions in development and disease. 23, 24 DNA methylation change also occurs in response to developmental perturbations, such as hypoxia. Altered levels of 5-methylcytosine, either genome wide or at specific gene loci, have been related to increased disease susceptibility, and dysregulation of DNA methylation has been linked to cardiovascular disease, type II diabetes, and cancer. [24] [25] [26] Most studies on DNA methylation have focused on gametogenesis, development, disease, and stem cell function by demonstrating how it regulates gene expression and cell differentiation. 23, [27] [28] [29] [30] Few studies, however, have been devoted to understand the roles of DNA methylation in heart development. Determining the landscape of DNA methylation in this process is an essential step for understanding how DNA methylation regulates the cardiac genes essential for heart development. Towards this end, we have applied a genome-wide approach in this study to profile developmental changes in DNA methylation in mouse embryonic hearts between E11.5 and E14.5. The morphogenic events occurring during this developmental window are less well studied than early morphogenic events such as the differentiation of cardiac cells. The results show that while the DNA methylome is stable during development, differential methylation occurs at a small subset of genes highly associated with cardiac tissue differentiation and heart development and reveal a regulatory relationship between differential DNA methylation and cardiac essential gene expression. Thus, these results provide new information on the regulation of cardiac gene expression and heart development by DNA methylation.
Methods

Animals (Mice)
ICR wild-type mice were bred in-house for timed pregnancies. Noontime on the day of first observing vaginal plugs was designated as embryonic day (E) 0.5. For Dnmt3b knockout studies, endocardial specific Cre mice (Nfatc1 Cre ) 9 were crossed with floxed Dnmt3b (DNA methyltransferase 3b) mice (obtained from The Jackson Laboratory) to delete Dnmt3b in heart valves. Conditional knockout (CKO) and control embryos were identified via PCR genotyping. All mouse experiments were performed according to the protocol approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine.
Methyl Sensitive Tiny Fragment Enrichment/ Massively Parallel Sequencing (MSFE/MPS)
Embryonic hearts from E11.5 or E14.5 were isolated from pregnant mice and non-cardiac tissues were removed. Genomic DNA was extracted from 4 groups of pooled hearts as described previously. 31 A total of 5 lg of extracted DNA from each group was used for a modified HELP-tagging assay. 32 We modified the original assay by replacing HpaII with HpyCH4IV, the restriction enzyme recognizing 5 0 -ACGT-3 0 sites and sensitive to methylation at the CG. After HpyCH4IV digestion, the sequencing libraries were generated using the Ligation Mediated PCR Assay (LMPA). 33 The generated libraries were submitted to the Epigenomics Shared Facility at the Albert Einstein College of Medicine for massively parallel sequencing. Sequencing was performed on individual libraries prepared from 2 biological replicates for each group. The quality of the sequencing results was determined by the parameters of length and peak value of sequence reads. The raw and processed data have been submitted to GEO (accession number: GSE55141).
Luminometric Methylation Assay to Validate the Global DNA Methylation
Global DNA methylation for each biological replicate, at both E11.5 and E14.5, was confirmed using the Luminometric Methylation Assay (LUMA) as described previously. 34, 35 Genomic DNA was digested for 4 hours with HpyCH4IV and EcoRI, purified and pyrosequenced at the Einstein Genomics Core.
MassArray
Loci with differential methylation, ranging from 0% to 100% determined by the massively parallel sequencing, were randomly selected and validated using Sequenom's MassArray. 36 Primers were designed using MethPrimer and T7 tags were added as per the Sequenom MassArray protocol (Table 1) . Genomic DNA (0.6 lg) from 3 replicates (for technical validation) and 2 replicates (for experimental validation) was bisulfite converted using the Zymo Research EZ DNA Methylation Kit prior to amplification using the MassArray Primers. Amplified bisulfite-converted genomic DNA was then subjected to MassArray on a Sequenom machine.
Bioinformatic Analysis to Profile Genome-Wide DNA Methylation
The sequencing reads were aligned to the mouse genome (mm9) and the number of mapped reads with their 5 0 ends starting at each ACGT site was recorded using the automated data analysis pipeline created by the Epigenomics Center and the Computational and Statistical Epigenomics Group at Albert Einstein College of Medicine. 32, 37 The read counts at individual ACGT sites from E11.5 and E14.5 were compared and sites with significantly different counts were determined by EdgeR, a Bioconductor package designed for analysis of count based genome-wide sequencing data. 38 The resultant sites were associated with genes if they were located to promoters, gene bodies, or within 50 kb of genes.
Gene Expression Analysis
Custom TaqMan Array 96-Well Fast Plates (Applied Biosystems) were designed for candidate genes prioritized based on degree of differential methylation, function, and presence of multiple-associated differentially methylated ACGT sites. RNA was extracted from pooled embryonic hearts from E11.5 or E14.5 (n=3 for each stage) and atrioventricular junctions isolated from 3 wild-type or 3 CKO embryos at E11.5 and E14.5 using Trizol Reagent (Invitrogen) and reverse transcribed using the SuperScript II reverse transcription kit (Invitrogen). DCt values were calculated, normalizing to an endogenous control, and fold change was calculated using the 2 ÀDDCt method. 39 
RNA In Situ Hybridization
RNA in situ hybridization for Has2 expression in E11.5 or E14.5 hearts was carried out as described previously. 5 
Immunohistochemistry
Immunohistochemistry (IHC) was carried out to determine expression of Dnmt3b in the developing heart using mouse monoclonal Dnmt3b antibody (Abcam 52A1018) (1:250), according to the Vector Labs mouse-on-mouse (M.O.M.) basic kit.
Statistical Analysis
Pearson correlation was used to evaluate the overall similarity of MSFE/MPS tag counts between E11.5 and E14.5 samples. Figure 5B remained, a few other differentially expressed genes included in Figure 5A would lose statistical support.
Results
Global DNA Methylation is Stable in the Developing Heart
To study the importance of DNA methylation in heart development, we carried out a genome-wide cytosine methylation analysis of E11.5 and E14. Figure 1A ), suggesting at the global level no significant methylation changes occurred between the 2 developmental stages. This finding of genome-wide stable DNA methylation in the developing hearts was supported by the LUMA data ( Figure 1B ).
Differential DNA Methylation Occurs Locally in the Developing Heart
We then catalogued the ACGT sites into genic sites (À50 kb of transcription start sites [TSS] to +0.5 kb of transcription end sites [TES] and intergenic sites) (Figure 2A) , with the former further separated into 3 types: promoter proximal sites (À5 kb to +0.5 kb of TSS), gene body sites (+0.5 kb of TSS to TES), and promoter distal or enhancer sites ( Figure 2B , top panel), and also determined the distribution of ACGT tag counts across the genome by intersecting the genome-wide ACGT methylation profiles with several genomic features, including CpG islands, CTCF-binding sites, RefSeq genes, repetitive elements, and regulatory elements ( Figure 2B , bottom panel). The gene annotation, CpG islands, and repeats were downloaded from the UCSC browser. Additionally, lists of regulatory elements for embryonic hearts were obtained from previous studies, including 3596 P300 binding sites identified for E11.5 hearts, 69 073 P300-marked enhancers, 14 874 CTCF sites, and 45 981 regions with the H3K27ac modification (a histone mark for active enhancer) for E14.5.
40-42
The results showed that gene promoters and regulatory regions, represented by either CpG islands or enhancers (defined by P300 occupancy in E11.5 or H3K27ac enrichment in E14.5) had significantly lower levels of DNA methylation than genomic background, as ACGT sites within these regions had increased numbers of tag counts (P<2.2e-16, t test). Similarly, CTCF-binding sites generally have low levels of methylation. This is consistent with previous reports that CTCF is associated with hypomethylated regions. 43 In contrast, repetitive regions showed significantly higher levels of DNA methylation, as ACGT sites in these regions had decreased numbers of tag counts (P<2.2e-16, t test). Unexpectedly, the E14.5 cardiac enhancers exhibited higher DNA methylation than the elements marked by either P300 or H3K27ac at E14.5 ( Figure 2B ). This is probably due to the fact that those enhancers were identified based largely on H3K4me1 modifications, which is enriched in both active and poised enhancers. 44, 45 Next, we chose up to 14 ACGT sites with a range of different tag counts, representing 0%, 25%, 50%, 75%, or 100% methylation by massively parallel sequencing, and determined A B Figure 2 . Distribution of DNA methylation across the mouse genome and various types of genomic elements in the developing heart. A, Cartoon depicting the genic regions (enhancer, promoter and genebody). B, Violin plot (a combination of a box plot and a kernel density plot) showing the distributions of tag counts for all ACGT (top) or differential methylated (bottom) sites in different genomic regions. As number of tag counts is inversely correlated to level of CG methylation, these plots indicate that gene promoters and regulatory regions exhibit significantly lower levels of DNA methylation than genomic background, and repetitive sequences are highly methylated. Plots in orange and yellow are for data from E11.5 and E14.5, respectively. TES indicates transcription end sites; TSS, transcription start sites. their levels of methylation by MassArray. The results indicated that tag count was inversely correlated with the percentage of cytosine methylation ( Figure 3A) , thereby confirming the precision of the MSFE/MPS in quantifying methylation level, ie, tag counts measured accurately both the global and regional DNA methylation. We then set out to investigate how much methylation changed in the developing hearts between E11.5 and E14.5. After normalization by sequencing depths, ACGT sites with at least 1 sequencing tag in any of the 4 samples were evaluated for differential methylation using 2 complementary approaches. We used EdgeR, which modeled the tag counts by a negative binomial distribution, to determine ACGT sites that showed differential methylation. The result indicated that the majority of the ACGT sites were not differentially methylated in the developing hearts between the 2 stages, as <1% of sites were found to have different tags (nominal P value <0.05) ( Figure 3B ). Among the small fraction (2901) of the %1.64 million analyzed ACGT sites that were differentially methylated, 1946 (67.1%) and 955 (32.9%) sites exhibited increased and decreased methylation in the late stage hearts, respectively (FDR<0.05) ( Figure 3C ). 38 Of note, for the majority of these sites, the degree of difference was <50%, with no sites switching from a fully methylated to an unmethylated state.
We also compared the percentage of differentially methylated ACGT sites at various genic and intergenic regions with the percentage of the total analyzed ACGT sites located within the same defined regions. We found that the differentially methylated sites were significantly enriched in gene bodies (P<2.2e-16, hypergeometric test), as 51.6% of the differentially methylated sites versus 42.2% of all assayed sites were located to gene bodies ( Figure 3D ). On the contrary, differentially methylated ACGT sites were under-represented in promoter (4.6%) and enhancer sites (13.9%), while 6.4% and 16.7% of all ACGT sites were in promoter-proximal and enhancer regions, respectively. In total, 2032 (70%) of the 2901 sites were associated with genes, with 65.1% of them showing increased methylation at E14.5. 
Differential DNA Methylation in the Developing Heart Links to Heart Development
To investigate the functional importance of the small set of genes exhibiting differential methylation, we used the software GREAT to characterize the 2901 differentially methylated sites for their potential regulatory roles. Of the only 7 significantly associated gene ontology (GO) terms for biological processes returned by GREAT, 4 of them were related to heart development and cardiac tissue growth (Figure 4 ), indicating a significant enrichment of cardiac essential genes that have differential DNA methylation during heart development. These genes include Erbb4, Gata6, Foxp1, Fgf2, Fgf9, Has2, Invs, Mef2c, Robo2, and Wnt2. For example, Foxp1 is important in cardiomyocyte proliferation, 42, 46 while signaling from Gata6 to
Wnt2 plays an important role in early cardiogenesis and inflow tract development, 47, 48 Mef2c plays an essential role in heart development as a regulator of cardiac myogenesis within the right ventricle, 49, 50 and Has2 plays a role in heart valve development. 6, 51 GREAT also reported that the affected genes were highly expressed in the cardiovascular system (P=5.3e-5) and they were implicated in vascular disease (P=1.4e-4) based on an analysis of Disease Ontology. 52 
Differential DNA Methylation Corresponds to Changes in Gene Expression in the Developing Heart
To directly test how the observed differential DNA methylation is related to gene expression changes in the developing heart, we picked 350 genes from the 1697 genes linked to the 2901 differentially methylated sites and performed qPCR to determine their expression levels in E11.5 and E14.5 hearts. These genes were chosen because they contained ACGT sites with a Figure 4 . Gene ontology (GO) terms for the genes with differential DNA methylation during heart development. The software GREAT was used to characterize the 2901 differentially methylated sites for function. Four of the only 7 GO terms returned are involved in heart development and cardiac tissue growth.
A B Table 2 . Continued ≥50% change in methylation between the 2 stages, their known function (such as roles in embryonic development preferentially heart development), and/or presence of multiple differentially methylated sites. Change in mRNA level was calculated using the 2 ÀDDCt method and genes were ranked based on fold change. 39 Of the 350 genes assayed in the gene expression analysis, 181 (51.7%) genes, including Erbb4, Has2, Invs, Robo2, and Vegfc, were differentially expressed between E11.5 and E14.5 (>1.2-fold change and P<0.05; adjusted for multiple testing), and among these, expression of 55 genes was upregulated whereas expression of 126 genes was downregulated ( Figure 5A , Table 2 ). Recent studies of the correlation between DNA methylation and gene expression have found that increased promoter and enhancer methylation often lead to gene silencing while DNA methylation at gene bodies corresponds with gene activation. 53 We therefore examined the functional correlation between differential gene expression and changes in DNA methylation. We found that among the top 15 downregulated genes at E14.5, 4 of them contained an increase in methylation of sites located within promoter or enhancer regions and an additional 4 showed decreased methylation in their gene bodies ( Figure 5B ). Of the top 15 upregulated genes, 4 had decreased methylation in their enhancers and 3 exhibited increased methylation in their gene bodies. We found that, while 12.7% (23) of the 181 differentially expressed genes contained differentially methylated sites within the promoter region, methylation of only 60.8% (14) of those genes was predictive of their expression difference between E11.5 and E14.5, and overall 43.6% (79) of genes had differentially methylated sites predictive of expression change. The findings suggest that not all DNA methylation is functional; most genes are regulated independent of methylation. 54 Nevertheless, the observed correlations between gene expression and DNA methylation during heart development do support that DNA methylation regulates expression of a subset of genes during heart development.
Increased DNA Methylation at Enhancers is Associated With Decreased Expression of the Cardiac-Essential Gene Has2 in the Developing Heart
These correlations suggest a regulatory relationship between DNA methylation and cardiac-important genes. Notably, Has2
is essential for endocardial to mesenchymal transformation and heart valve formation. 6, 51, 55, 56 Gene network analysis using the Genemania open freeware (http://www.genemania.org) further revealed potential genetic and/or physical interactions among genes or pathways involved in heart development. The top 20 genes that were identified to interact (either genetically or physically) with Has2 by the network analysis were significantly enriched with functions involved in heart development. These genes included Cdh2, Epo, Kcna5, Myocd, Tbx20, Hand1, Mef2c, and Nfatc4 ( Figure 6 ). 49, [57] [58] [59] Regulation of these genes by DNA methylation to influence their expression will ultimately affect their A B Figure 6 . sion was predominately expressed in the endocardial cells and their mesenchymal progeny cells that form the primitive heart valves at E11.5, but its expression markedly diminished by E14.5 ( Figure 7C ), consistent with its function in endocardial to mesenchymal transformation around E11.5 for heart valve development.
Dnmt3b Suppresses Expression of the CardiacEssential Gene Has2 in the Developing Heart
We next chose to determine experimentally the function of DNA methylation in Has2 expression in the developing heart valves. To overcome the difficulty of not being able to directly assay the in vivo role of methylation of the Has2 enhancer on the expression of the gene in the developing heart, we inactivated the activity of DNA methyltransferase 3b (Dnmt3b), which is responsible for de novo methylation during embryonic development. 22 First, we showed that, like Has2, Dnmt3b was expressed predominately in the endocardial cells, precursor cells for the heart valves ( Figure 7D ). The expression pattern of Dnmt3b suggests that it has a role in DNA methylation in the endocardial cell lineages and may therefore regulate Has2 expression in the developing heart valves. Indeed, deletion of Dnmt3b in the endocardial cells and their valve progeny, using the endocardial-specific Nfatc1 Cre mice ( Figure 7E ), 9 
resulted in significantly increased
Has2 expression in the developing heart valves at E11.5 and E14.5 ( Figure 7F ). The results support that DNA methylation of the Has2 enhancer plays a role in repressing its expression during heart development.
Discussion
In this study, we generated a developmental profile of DNA methylation using methyl sensitive tiny fragment enrichment coupled with massively parallel sequencing (MSFE/MPS). Greater coverage and increased sensitivity for the detection of methylation are achieved using this method compared with microarray-based techniques. The method also provides more detailed information specific for ACGT sites and is capable of detecting intermediate levels of methylation, allowing for detection of modest changes in methylation. 60 Our technique was adapted from the HpaII tiny fragment enrichment by ligation mediated PCR (HELP)-tagging assay developed by Suzuki et al 32, 33 In the original HELP-tagging assay a methylation sensitive restriction enzyme, HpaII, is used to assess methylation of CpG dinucleotides located within its recognition site 5 0 -CCGG-3 0 . We modified this technique by using a different methylation-sensitive restriction enzyme, HpyCH4IV, whose recognition site is 5 0 -ACGT-3 0 even though it lacks a methylation-insensitive isoschizomer.
Previous studies have confirmed that sequencing reads/tags from a single methylation sensitive restriction enzyme without its isoschizomer are highly correlated with methylation status. 32, 61 Furthermore, we used independent validation methods, such as LUMA and MassArray to confirm methylation levels determined by the MSFE/MPS. HpyCH4IV provides comparable genome coverage to HpaII, having 1.7 million recognition sites located throughout the genome. Future studies using both enzymes will not only double the coverage but also examine and compare DNA methylation in both CG rich and non-CG rich regions. In addition, the use of HpyCH4IV will, in future studies, allow us to directly examine, in a genome-wide manner, the effect of methylation on transcription factor binding sites such as Hif1a, whose consensus binding sequence is 5
0 -ACGTG-3 0 and has been shown to be regulated by DNA methylation. 62 The original analytical pipeline was also modified to analyze our MPS data generated by using HpyCH4IV. 37 Within the HELP-tagging protocol an internal experimental control is used in which contaminating fragments are recognized based on the absence of the digested restriction site. 60 Additionally, to better identify differentially methylated sites between developmental stages, we generated a threshold to determine levels of methylation at individual loci. We employed these modifications to generate a genome wide developmental profile of methylation at ACGT sites in the developing heart. The results showed no significant global change in methylation over mid-stage heart development, although our study did not include the repetitive regions of the genome as they could not be aligned and thus discarded in the pipeline. We further confirmed that there is no significant change in global methylation patterns using LUMA. Although drastic changes in global DNA methylation are not present during heart development, differential methylation was detected at a small subset of individual loci throughout the genome in this study. Furthermore, we detected a number of differentially methylated sites in which the change in methylation between E11.5 and E14.5 corresponds with the observed change in expression of the nearby gene, suggesting that there is a regulatory relationship between DNA methylation and the expression of cardiac-important genes including Has2.
Has2 has previously been identified to be essential for heart development, playing a role in epicardial cell differentiation, heart valve development, and septation. 51, 55 A DNA methylation-regulated cardiac gene program was generated by performing a network analysis for Has2 using Genemania. Network analysis revealed multiple relationships between Has2 and other cardiac-important gene products, including previously mentioned Tbx20, involved in endocardial cushion formation and heart valve remodeling, 57 Hand 1 involved in ventricle morphogenesis, 58 and Nfatc4, a member of the nuclear factor of activated T-cell family that are known to be essential for heart development. 59 Additional connections have been identified between Has2 and Gjc1 (Connexin45), known to play an important role in cardiac morphogenesis and conduction, 63 and Cdh2, Epo, Kcna5, Mef2c, and Myocd, which are essential for heart development and function. We further studied methylation of Has2 and its expression in the developing heart in detail, as it has an increase in enhancer methylation that corresponds with a decrease in its expression over mid-stage heart development in the developing heart valves. We showed by qPCR analysis, RNA in situ hybridization, and genetic knockout that Dnmt3b regulates Has2 expression, possibly through its enhancer methylation.
In this study we were able to assay 1.64 million ACGT sites for potential changes in DNA methylation during mid-stage cardiac development, identifying 2901 differentially methylated sites, and determined a number of developmentally important cardiac genes that are likely to be regulated by DNA methylation. However, current methods for studying functionality of DNA methylation at specific sites in the developing heart are limited. We circumvented this limitation by revealing the dependence of Has2 expression on Dnmt3b expression in the developing heart valves. Our results are mainly discovery and by necessity preliminary, and will require a much larger sample size to detect more sites with more subtle DNA methylation changes between the 2 developmental stages.
In conclusion, our results support an essential role for DNA methylation in the regulation of cardiac essential genes during heart development and suggest abnormal DNA methylation may contribute to the pathogenesis of congenital heart disease. Using this study as a starting point, we plan to investigate further candidate genes as well as the role of additional epigenetic modifications that may play a role in heart development and disease.
